ROSEN, A LEADING LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, NY–(Newsfile Corp. – January 13, 2025) – WHY? The Rosen Law Firm, a global investor protection law firm, reminds purchasers of Applied Therapeutics, Inc. (NASDAQ: NASDAQ: ) securities between January 3, 2024 and December 2, 2024, both dates inclusive ( “Class period”). the important thing February 18, 2025 lead plaintiff deadline.

SO WHAT? If you purchased Applied Therapeutics securities during the Class Period, you may be entitled to a refund without paying any cash fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT? To join the applicable therapeutic class action, visit https://rosenlegal.com/submit-form/?case_id=32500 or call Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com. A class action lawsuit has already been filed. If you want to act as the main plaintiff, you must move to court no later than February 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in leading the litigation.

WHY CHOOSE ROSEN LAW? We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices do not have comparable experience, resources or the recognition of any meaningful peers. Many of these firms do not actually handle securities class actions, but are simply brokers who refer clients or partner with the law firms that actually litigate the cases. Choose Wisely The Rosen Law Firm represents investors worldwide, focusing its practice in securities class action and shareholder derivative litigation Ranked #1 by Class Action: (WA:) Services for securities class actions in 2017. The company has been ranked in the top 4 every year since 2013. In 2019 alone, the company secured more than 438 million dollars for investors Founding partner Lawrence Rosen was named a titan of plaintiffs’ counsel by law360.Many of the firm’s attorneys have been recognized By Lawdragon and Super Lawyers.

DETAILS OF THE CASE. According to the lawsuit, the statements made during the class were false and/or materially misleading because they concealed and misrepresented the clinical trial protocols and procedures applied at Applied Therapeutics. Therefore, the defendants gave investors the false impression that the protocol and good clinical Practices were properly followed. The lawsuit alleges that, in fact, Applied Therapeutics did not follow trial protocol and good clinical practices, which in turn created an extremely serious risk that trial data will be rejected by the US Food and Drug Administration (“FDA”). The context of the new drug application: When the real details came to market, the lawsuit alleges that investors suffered losses.

To join the Applied Therapeutics Class Action, visit https://rosenlegal.com/submit-form/?case_id=32500 call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com.

No class has been certified. You may not be represented by an attorney. You may also choose to remain an absent class member at this time potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn at https://www.linkedin.com/company/the-rosen-law-firm or on Twitter at https://twitter.com/rosen_firm or on Facebook (NASDAQ: ). https:/ /www.facebook.com/rosenlawfirm.

Advertisement of a lawyer. Past results do not guarantee a similar result.

——————————

To view the original version of this press release, visit https://www.newsfilecorp.com/release/237072